Thalidomide: An old sedative-hypnotic with anticancer activity?

G. Gasparini, A. Morabito, E. Magnani, D. Gattuso, B. Capaccetti, A. M. Alberti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s. This paper reviews the possible mechanisms of its teratogenic effect, its new therapeutic indications, the proposed mechanisms for its antitumor activity and, finally, reviews published studies of its application in oncology. Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer. Furthermore, a beneficial effect of the drug has been proposed in cancer-related cachexia, which merits further investigation. Well-designed, randomized studies are warranted to establish the possible indications of thalidomide as an antitumor compound.

Original languageEnglish
Pages (from-to)1302-1308
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number9
Publication statusPublished - 2001

Fingerprint

Thalidomide
Hypnotics and Sedatives
Glutamates
Cachexia
Glioblastoma
Multiple Myeloma
Renal Cell Carcinoma
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Angiogenesis
  • Antitumor agent
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gasparini, G., Morabito, A., Magnani, E., Gattuso, D., Capaccetti, B., & Alberti, A. M. (2001). Thalidomide: An old sedative-hypnotic with anticancer activity? Current Opinion in Investigational Drugs, 2(9), 1302-1308.

Thalidomide : An old sedative-hypnotic with anticancer activity? / Gasparini, G.; Morabito, A.; Magnani, E.; Gattuso, D.; Capaccetti, B.; Alberti, A. M.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 9, 2001, p. 1302-1308.

Research output: Contribution to journalArticle

Gasparini, G, Morabito, A, Magnani, E, Gattuso, D, Capaccetti, B & Alberti, AM 2001, 'Thalidomide: An old sedative-hypnotic with anticancer activity?', Current Opinion in Investigational Drugs, vol. 2, no. 9, pp. 1302-1308.
Gasparini G, Morabito A, Magnani E, Gattuso D, Capaccetti B, Alberti AM. Thalidomide: An old sedative-hypnotic with anticancer activity? Current Opinion in Investigational Drugs. 2001;2(9):1302-1308.
Gasparini, G. ; Morabito, A. ; Magnani, E. ; Gattuso, D. ; Capaccetti, B. ; Alberti, A. M. / Thalidomide : An old sedative-hypnotic with anticancer activity?. In: Current Opinion in Investigational Drugs. 2001 ; Vol. 2, No. 9. pp. 1302-1308.
@article{39999139c7b04adbaaa4954721871ca4,
title = "Thalidomide: An old sedative-hypnotic with anticancer activity?",
abstract = "Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s. This paper reviews the possible mechanisms of its teratogenic effect, its new therapeutic indications, the proposed mechanisms for its antitumor activity and, finally, reviews published studies of its application in oncology. Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer. Furthermore, a beneficial effect of the drug has been proposed in cancer-related cachexia, which merits further investigation. Well-designed, randomized studies are warranted to establish the possible indications of thalidomide as an antitumor compound.",
keywords = "Angiogenesis, Antitumor agent, Thalidomide",
author = "G. Gasparini and A. Morabito and E. Magnani and D. Gattuso and B. Capaccetti and Alberti, {A. M.}",
year = "2001",
language = "English",
volume = "2",
pages = "1302--1308",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "9",

}

TY - JOUR

T1 - Thalidomide

T2 - An old sedative-hypnotic with anticancer activity?

AU - Gasparini, G.

AU - Morabito, A.

AU - Magnani, E.

AU - Gattuso, D.

AU - Capaccetti, B.

AU - Alberti, A. M.

PY - 2001

Y1 - 2001

N2 - Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s. This paper reviews the possible mechanisms of its teratogenic effect, its new therapeutic indications, the proposed mechanisms for its antitumor activity and, finally, reviews published studies of its application in oncology. Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer. Furthermore, a beneficial effect of the drug has been proposed in cancer-related cachexia, which merits further investigation. Well-designed, randomized studies are warranted to establish the possible indications of thalidomide as an antitumor compound.

AB - Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s. This paper reviews the possible mechanisms of its teratogenic effect, its new therapeutic indications, the proposed mechanisms for its antitumor activity and, finally, reviews published studies of its application in oncology. Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer. Furthermore, a beneficial effect of the drug has been proposed in cancer-related cachexia, which merits further investigation. Well-designed, randomized studies are warranted to establish the possible indications of thalidomide as an antitumor compound.

KW - Angiogenesis

KW - Antitumor agent

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0034823203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034823203&partnerID=8YFLogxK

M3 - Article

C2 - 11717819

AN - SCOPUS:0034823203

VL - 2

SP - 1302

EP - 1308

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 9

ER -